Benazepril

Main information

  • Trade name:
  • Benazepril hydrochloride Le Vet 5 mg tablets for dogs
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Benazepril hydrochloride Le Vet 5 mg tablets for dogs
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • benazepril
  • Therapeutic area:
  • Dogs Non Food

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • NL/V/0126/002
  • Authorization date:
  • 07-07-2011
  • EU code:
  • NL/V/0126/002
  • Last update:
  • 09-08-2016

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

PartIB1Summaryofproductcharacteristics

1.NAMEOFTHEVETERINARYMEDICINALPRODUCT

NL:BenazeprilhydrochlorideLeVet5mgtablettenvoorhonden

AT:Benakor5mg,TablettenfürHunde

BE:BenakorF5mgtablettenvoorhonden

CZ:BenakorF5mg,tabletypropsy

EE:BenakorF5mgtabletidkoertele

ES:Benakor5mgcomprimidosparaperros

FI:Benakorvet5mgtabletti

FR:BenakorF5compriméspourchiens

IE:Benakor5mgtabletsfordogs

IT:Benakor5mgcompressepercani

LU:BenakorF5mgcompriméspourchiens

NO:Benakorvet.5mgtablettertilhund

PL:BenakorF5mgtabletkidlapsów

PT:Benakor5mgcomprimidosparacães

SK:BenakorF5mgtabletyprepsov

2.QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activesubstance:4.6mgbenazepril(equivalentto5mgbenazeprilhydrochloride)

Excipient(s):Colourant:Ironoxides(E172)0.5mg

Forafulllistofexcipients,seesection6.1.

3.PHARMACEUTICALFORM

Yellowoblongdivisibletablets,withabreakmarkononeside.

4.CLINICALPARTICULARS

4.1Targetspecies

Dog

4.2Indicationsforuse,specifyingthetargetspecies

Symptomatictreatmentofcongestiveheartfailureindogswithorwithoutadjuncttherapyusedinthe

treatmentofheartfailure.

4.3Contraindications

Donotuseinanydogthathasevidenceofcardiacoutputfailureduetoaorticstenosis,mitralvalve

stenosisorpulmonarystenosisorincaseofhypotension.

DonotuseincaseofknownhypersensitivitytoACEinhibitorsortoanyoftheingredientsoftheproduct.

Seesection4.7

4.4Specialwarningsforeachtargetspecies

None

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Noevidenceofrenaltoxicitytotheproducthasbeenobservedindogsduringclinicaltrials.However,as

isroutineincasesofrenalinsufficiency,itisrecommendedtomonitorplasmaureaandcreatininelevels.

Donotabruptlystoporreducetherapy.

Specialprecautionstobetakenbythepersonadministeringthemedicinalproducttoanimals

Washhandsafteruse.

Pregnantwomenshouldtakespecialcaretoavoidaccidentalexposure,becauseACEinhibitorshavebeen

foundtoaffecttheunbornchildduringpregnancyinhumans.

Incaseofaccidentalingestionbychildren,seekmedicaladviceimmediatelyandshowthepackageleaflet

orthelabeltothephysician.

4.6Adversereactions(frequencyandseriousness)

-atthestartoftreatmentadecreaseofbloodpressuremayoccur.

-inrarecasesfatigueordrowsinessmaybeobserved.

-benazeprilhydrochloridemayleadtoincreasedplasmacreatinineconcentrations.

-onrareoccasionstransientsignsofhypotension,suchaslethargyandataxiamayoccur.

4.7Useduringpregnancyorlactation

Donotuseinpregnantornursingbitchesorinbitchesintendedforbreeding.Safetyoftheproducthasnot

beentestedinbreeding,pregnantorlactatingdogs.Laboratorystudiesinratshaveshownembryotoxic

effectsofbenazeprilatnon-maternotoxicdoses(urinarytractabnormalitiesinthefoetus).Inhumans,

ACEinhibitorshavebeenfoundtobeteratogenicduringpregnancy.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Indogswithheartfailure,benazeprilhasbeengivenincombinationwithdigoxin,diureticsandanti-

arrhythmicdrugswithoutdemonstrableadverseinteractions.

Inman,thecombinationofACEinhibitorsandNSAIDscanleadtoreducedantihypertensiveefficacyor

impairedrenalfunction.Thecombinationofbenazeprilandotherantihypertensiveagents(e.g.calcium

channelblockers,beta-blockersordiuretics),anaestheticsorsedativesmayleadtoadditivehypotensive

effects.ThereforeconcurrentuseofNSAIDsorothermedicationwithahypotensiveeffectshouldbe

consideredwithcare.Renalfunctionandsignsofhypotension(lethargy,weakness,etc.)shouldbe

monitoredcloselyandtreatedasnecessary.

Interactionswithpotassiumpreservingdiureticslikespironolactone,triamterenoramiloridcannotbe

ruledout.Itisrecommendedtomonitorplasmapotassiumlevelswhenusingbenazeprilincombination

withapotassiumsparingdiureticaslifethreateningreactionsareapossibility.

4.9Amountstobeadministeredandadministrationroute

Therecommendedoraldoseis0.25mgbenazeprilhydrochloride/kgbodyweightoncedaily.Thedose

maybedoubled(stilladministeredoncedaily),ifjudgedclinicallynecessaryandadvisedbythe

veterinarysurgeon.

Incaseofusinghalvedtablets:Puttheremaininghalfofadividedtabletbackintheblisterpocketand

storeitinadryplacebelow25°C.Usetheremainingtablethalfforthenextadministration.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Morphologicalchangessuchashypertrophyandhyperplasiaofthejuxtaglomerularapparatus,increaseof

ureaandloweredheartweightinhealthydogsduetoinvolutionhasbeenobservedafterdosesofmore

than10mg/kg.

Transientreversiblehypotensionmayoccurincasesofaccidentaloverdosage.Symptomatictreatment

consistsofintravenousinfusionofwarmisotonicsalinesolution.

4.11Withdrawalperiod(s)

Notapplicable.

5.PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:ACEinhibitors,plain

ATCvetcode:QC09AA07

5.1Pharmacodynamicproperties

Benazeprilhydrochlorideisapro-drughydrolysedinvivotobenazeprilate.Benazeprilateisahighly

potentandselectiveinhibitorofangiotensinconvertingenzyme(ACE),thuspreventingtheconversionof

inactiveangiotensinItoactiveangiotensinII.Therefore,itblockseffectsmediatedbyangiotensinII,

includingvasoconstrictionofbotharteriesandveins,retentionofsodiumandwaterbythekidneyand

modellingeffects(includingpathologicalcardiahypertrophyanddegenerativerenalchanges).

Theproductcauseslong-lastinginhibitionofplasmaACEactivityindogs,withmorethan95%inhibition

atpeakeffectandsignificantactivity(>80%indogs)persisting24hoursafterdosing.Itreducestheblood

pressureandvolumeloadontheheartindogswithheartfailure.

Onsetofclinicalefficacycanbeexpectedinapproximately1weekafterinitiationoftherapywith

benazeprilhydrochloride.

5.2Pharmacokineticparticulars

Afteroraladministrationofbenazeprilhydrochloride,peaklevelsofbenazeprilareattainedrapidly(tmax

1.1hindogs)anddeclinequicklyasthedrugispartiallymetabolisedbyliverenzymestobenazeprilate.

Indogs,unchangedbenazeprilandhydrophilicmetabolitesaccountfortheremainder.Indogs,peak

benazeprilateconcentrations(Cmaxof384.16ng/mlafteradoseof1.6mg/kgoftheproduct)are

achievedwithatmaxof1.1hithersystemicbioavailabilityisincomplete(~13%indogs)dueto

incompleteabsorption(38%indogs).

Benazeprilateiseliminatedwithat1/2of2.8hindogs.Benazeprilandbenazeprilateareextensively

boundtoplasmaproteins,andintissuesarefoundmainlyintheliverandthekidney.

Thereisnosignificantdifferenceinthepharmacokineticsofbenazeprilatewhenbenazeprilhydrochloride

isadministeredtofedorfasteddogs.

Benazeprilateisexcreted54%viathebiliaryand46%viatheurinaryrouteindogs.Theclearanceof

benazeprilateisnotaffectedindogswithimpairedrenalfunctionandthereforenoadjustmentofthedose

isrequiredincasesofrenalinsufficiency.

6.PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Silicacolloidalanhydrous(E551)

Microcrystallinecellulose(E460)

Lactoseanhydrous

ColorconPigmentBlend22870yellow(Ironoxides,E172)

Sodiumcyclamate(E952)

SodiumstarchglycolateTypeA

Magnesiumstearate(E470b).

6.2Incompatibilities

Notapplicable.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:

PVC/PE/PVDC-Aluminiumblister:12months.

Aluminium/Aluminiumblister:18months.

6.4.Specialprecautionsforstorage

Donotstoreabove25ºCStoreintheoriginalpackage.

6.5Natureandcompositionofimmediatepackaging

1cartoncontains:

1,2,3,4,5,6or7PVC/PE/PVDC/Alu-foilblistersof14tabletseach.

or

1,2,3,4,5,6,7Alu/Alu-foilblistersof14tabletseach.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproductorwaste

materialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinarymedicinal

productsshouldbedisposedofinaccordancewithlocalrequirements.

7.MARKETINGAUTHORISATIONHOLDER

LeVetB.V.

Willeskop212

3421GWOudewater

TheNetherlands

8.MARKETINGAUTHORISATIONNUMBER

<localrequirement>

9.DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

<localrequirement>

10DATEOFREVISIONOFTHETEXT

<localrequirement>

PartIB2 Proposalforpackaging,labellingandpackageinsert

1.Labelling

PARTICULARSTOAPPEARONTHEOUTERPACKAGE

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

BenazeprilhydrochlorideLeVet5mgtabletsfordogs

benazeprilhydrochloride

2. STATEMENTOFACTIVEANDOTHERSUBSTANCES

4.6mgbenazepril(equivalentto5mgbenazeprilhydrochloride)

Colouringaid:Ironoxides(E172)0.5mg

3. PHARMACEUTICALFORM

Tablet

4. PACKAGESIZE

14,28,42,56,70,84or98tablets

5. TARGETSPECIES

Dog

6. INDICATION(S)

Symptomatictreatmentofcongestiveheartfailureindogswithorwithoutadjuncttherapyusedinthe

treatmentofheartfailure.

7. METHODANDROUTE(S)OFADMINISTRATION

Fororaluse

Readthepackageleafletbeforeuse.

8. WITHDRAWALPERIOD

9. SPECIALWARNING(S),IFNECESSARY

Washhandsafteruse

Pregnantwomenshouldtakespecialcaretoavoidaccidentalexposure,becauseACEinhibitorshavebeen

foundtoaffecttheunbornchildduringpregnancyinhumans.

Incaseofaccidentalingestionbychildren,seekmedicaladviceimmediatelyandshowthislabeltothe

doctor.

10. EXPIRYDATE

EXP{month/year}

11. SPECIALSTORAGECONDITIONS

Donotstoreabove25ºC.

Storeintheoriginalpackage

12. SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTSORWASTE

MATERIALS,IFANY

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinarymedicinal

productsshouldbedisposedofinaccordancewithlocalrequirements.

13. THEWORDS“FORANIMALTREATMENTONLY”ANDCONDITIONSOR

RESTRICTIONSREGARDINGSUPPLYANDUSE,ifapplicable

Foranimaltreatmentonly

14. THEWORDS“KEEPOUTOFTHEREACHANDSIGHTOFCHILDREN”

Keepoutofthereachandsightofchildren.

15. NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDER

LeVetB.V.

Willeskop212

3421GWOudewater

TheNetherlands

16. MARKETINGAUTHORISATIONNUMBER(S)

17. MANUFACTURER’SBATCHNUMBER

Batch{number}

MINIMUMPARTICULARSTOAPPEARONBLISTERSORSTRIPS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

BenazeprilhydrochlorideLeVet5mgtabletsfordogs

benazeprilhydrochloride

2. NAMEOFTHEMARKETINGAUTHORISATIONHOLDER

LeVet

3. EXPIRYDATE

EXP{month/year}

4. BATCHNUMBER

Batch{number}

5. THEWORDS“FORANIMALTREATMENTONLY”

Foranimaltreatmentonly

2.Packageinsert

PACKAGELEAFLET

BenazeprilhydrochlorideLeVet5mgtabletsfordogs

1. NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDERANDOF

THEMANUFACTURINGAUTHORISATIONHOLDERRESPONSIBLEFORBATCH

RELEASE,IFDIFFERENT

Marketingauthorisationholder:

LeVetB.V.

Willeskop212

3421GWOudewater

TheNetherlands

Manufacturerforthebatchrelease:

ProdulabPharmaB.V.

Forellenweg16

4841SJRaamsdonksveer

TheNetherlands

2. NAMEOFTHEVETERINARYMEDICINALPRODUCT

BenazeprilhydrochlorideLeVet5mgtabletsfordogs

benazeprilhydrochloride

3. STATEMENTOFTHEACTIVESUBSTANCE(S)ANDOTHERINGREDIENT(S)

Eachtabletcontains:

Activeingredient: 4.6mgbenazepril(equivalentto5mgbenazeprilhydrochloride)

Colouringaid: Ironoxides(E172)0.5mg

4. INDICATION(S)

Symptomatictreatmentofcongestiveheartfailureindogswithorwithoutadjuncttherapyusedinthe

treatmentofheartfailure

5. CONTRAINDICATIONS

Donotuseinanydogthathasevidenceofcardiacoutputfailureduetoaorticstenosis,mitralvalve

stenosisorpulmonarystenosisorincaseofhypotension.

DonotuseincaseofknownhypersensitivitytoACEinhibitorsortoanyoftheingredientsoftheproduct.

Seesection12.

6. ADVERSEREACTIONS

- atthestartoftreatmentadecreaseofbloodpressuremayoccur.

- inrarecasesfatigueordrowsinessmaybeobserved.

- benazeprilhydrochloridemayleadtoincreasedplasmacreatinineconcentrations.

- onrareoccasionstransientsignsofhypotension,suchaslethargyandataxiamayoccur.

7. TARGETSPECIES

Dogs

8. DOSAGEFOREACHSPECIES,ROUTE(S)ANDMETHODOFADMINISTRATION

Therecommendedoraldoseis0.25mgbenazeprilhydrochloride/kgbodyweightoncedaily.Thedose

maybedoubled(stilladministeredoncedaily),ifjudgedclinicallynecessaryandadvisedbythe

veterinarysurgeon.

Incaseofusinghalvedtablets:Puttheremaininghalfofadividedtabletbackintheblisterpocketand

storeitinadryplacebelow25°C.Usetheremainingtablethalfforthenextadministration.

9. ADVICEONCORRECTADMINISTRATION

Foranimaltreatmentonly.Fororaluseonly.

10. WITHDRAWALPERIOD

Notapplicable.

11. SPECIALSTORAGEPRECAUTIONS

Keepoutofthereachandsightofchildren.

Donotstoreabove25ºC.

Storeintheoriginalpackage

DonotuseaftertheexpirydatestatedonthecartonafterEXP.

12. SPECIALWARNING(S)

Noevidenceofrenaltoxicitytotheproducthasbeenobservedindogsduringclinicaltrials.However,as

isroutineincasesofrenalinsufficiency,itisrecommendedtomonitorplasmaureaandcreatininelevels.

Donotabruptlystoporreducetherapy.

Washhandsafteruse.

Pregnantwomenshouldtakespecialcaretoavoidaccidentalexposure,becauseACEinhibitorshavebeen

foundtoaffecttheunbornchildduringpregnancyinhumans.

Incaseofaccidentalingestionbychildren,seekmedicaladviceimmediatelyandshowthepackageleaflet

orthelabeltothephysician.

Donotuseinpregnantornursingbitchesorinbitchesintendedforbreeding.Safetyoftheproducthasnot

beentestedinbreeding,pregnantorlactatingdogs.Laboratorystudiesinratshaveshownembryotoxic

effectsofbenazeprilatnon-maternotoxicdoses(urinarytractabnormalitiesinthefoetus).Inhumans,

ACEinhibitorshavebeenfoundtobeteratogenicduringpregnancy.

Morphologicalchangessuchashypertrophyandhyperplasiaofthejuxtaglomerularapparatus,increaseof

ureaandloweredheartweightinhealthydogsduetoinvolutionhasbeenobservedafterdosesofmore

than10mg/kg.

Transientreversiblehypotensionmayoccurincasesofaccidentaloverdosage.Symptomatictreatment

consistsofintravenousinfusionofwarmisotonicsalinesolution.

Indogswithheartfailure,benazeprilhasbeengivenincombinationwithdigoxin,diureticsandanti-

arrhythmicdrugswithoutdemonstrableadverseinteractions.Inman,thecombinationofACEinhibitors

andNSAIDscanleadtoreducedantihypertensiveefficacyorimpairedrenalfunction.Thecombinationof

benazeprilandotherantihypertensiveagents(e.g.calciumchannelblockers,beta-blockersordiuretics),

anaestheticsorsedativesmayleadtoadditivehypotensiveeffects.ThereforeconcurrentuseofNSAIDsor

othermedicationwithahypotensiveeffectshouldbeconsideredwithcare.Renalfunctionandsignsof

hypotension(lethargy,weakness,etc.)shouldbemonitoredcloselyandtreatedasnecessary.

Interactionswithpotassiumpreservingdiureticslikespironolactone,triamterenoramiloridcannotbe

ruledout.Itisrecommendedtomonitorplasmapotassiumlevelswhenusingbenazeprilincombination

withapotassiumsparingdiureticaslifethreateningreactionsareapossibility.

13. SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTORWASTE

MATERIALS,IFANY

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinarymedicinalproducts

shouldbedisposedofinaccordancewithlocalrequirements.

14. DATEONWHICHTHEPACKAGELEAFLETWASLASTAPPROVED

<localrequirement>

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

4-6-2018

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69), to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.

FDA - U.S. Food and Drug Administration

4-6-2018

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System   by Hospira: Recall - Due to the Potential Presence of Particulate Matter

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System by Hospira: Recall - Due to the Potential Presence of Particulate Matter

The patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.

FDA - U.S. Food and Drug Administration

28-11-2018

Econor (Elanco GmbH)

Econor (Elanco GmbH)

Econor (Active substance: Valnemulin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8038 of Wed, 28 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/42/T/54

Europe -DG Health and Food Safety

26-11-2018

Wakix (Bioprojet Pharma)

Wakix (Bioprojet Pharma)

Wakix (Active substance: Pitolisant hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7974 of Mon, 26 Nov 2018

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Active substance: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride) - Orphan designation - Commission Decision (2018)7791 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/040/18

Europe -DG Health and Food Safety

13-11-2018

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7576 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/233/16/T/01

Europe -DG Health and Food Safety

13-11-2018

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7575 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/140/13/T/01

Europe -DG Health and Food Safety

1-11-2018

Dexdomitor (Orion Corporation)

Dexdomitor (Orion Corporation)

Dexdomitor (Active substance: dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7380 of Thu, 01 Nov 2018

Europe -DG Health and Food Safety

31-10-2018

Evista (Daiichi Sankyo Europe GmbH)

Evista (Daiichi Sankyo Europe GmbH)

Evista (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7342 of Wed, 31 Oct 2018

Europe -DG Health and Food Safety

26-9-2018

FORTEKOR PLUS (Elanco GmbH)

FORTEKOR PLUS (Elanco GmbH)

FORTEKOR PLUS (Active substance: pimobendan / benazepril) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6321 of Wed, 26 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2804/T/11

Europe -DG Health and Food Safety

26-9-2018

Sileo (Orion Corporation)

Sileo (Orion Corporation)

Sileo (Active substance: Dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)6325 of Wed, 26 Sep 2018

Europe -DG Health and Food Safety

10-8-2018

Brinavess (Correvio)

Brinavess (Correvio)

Brinavess (Active substance: vernakalant hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5523 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1215/T/31

Europe -DG Health and Food Safety

30-7-2018

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Active substance: ertugliflozin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5103 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4314/T/2

Europe -DG Health and Food Safety

30-7-2018

Ceplene (Noventia Pharma Srl)

Ceplene (Noventia Pharma Srl)

Ceplene (Active substance: Histamine dihydrochloride) - Centralised - Renewal - Commission Decision (2018)5116 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/796/R/36

Europe -DG Health and Food Safety

23-7-2018

Optruma (Eli Lilly Nederland B.V.)

Optruma (Eli Lilly Nederland B.V.)

Optruma (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4893 of Mon, 23 Jul 2018

Europe -DG Health and Food Safety

12-7-2018

Econor (Elanco Europe Ltd)

Econor (Elanco Europe Ltd)

Econor (Active substance: Valnemulin hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4580 of Thu, 12 Jul 2018

Europe -DG Health and Food Safety

11-7-2018

Ariclaim (Eli Lilly Nederland B.V.)

Ariclaim (Eli Lilly Nederland B.V.)

Ariclaim (Active substance: duloxetine hydrochloride) - Centralised - Withdrawal - Commission Decision (2018)4515 of Wed, 11 Jul 2018

Europe -DG Health and Food Safety

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency

3-7-2018

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4254 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/896/T/90

Europe -DG Health and Food Safety

3-7-2018

Ristfor (Merck Sharp and Dohme B.V.)

Ristfor (Merck Sharp and Dohme B.V.)

Ristfor (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4249 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1235/T/77

Europe -DG Health and Food Safety

3-7-2018

Velmetia (Merck Sharp and Dohme B.V.)

Velmetia (Merck Sharp and Dohme B.V.)

Velmetia (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4252 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/862/T/93

Europe -DG Health and Food Safety

3-7-2018

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4251 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/861/T/90

Europe -DG Health and Food Safety

29-6-2018

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (Active substance: (R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride) - Orphan designation - Commission Decision (2018)4173 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/003/18

Europe -DG Health and Food Safety

14-6-2018

Kuvan (BioMarin International Limited)

Kuvan (BioMarin International Limited)

Kuvan (Active substance: sapropterin dihydrochloride) - Centralised - Yearly update - Commission Decision (2018)3859 of Thu, 14 Jun 2018

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3809 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/092/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3808 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/084/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/794 (Celgene Europe B.V.)

EU/3/10/794 (Celgene Europe B.V.)

EU/3/10/794 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3803 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/069/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/888 (Gilead Sciences Ireland UC)

EU/3/11/888 (Gilead Sciences Ireland UC)

EU/3/11/888 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3802 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/152/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/887 (Gilead Sciences Ireland UC)

EU/3/11/887 (Gilead Sciences Ireland UC)

EU/3/11/887 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3801 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/020/11/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/886 (Gilead Sciences Ireland UC)

EU/3/11/886 (Gilead Sciences Ireland UC)

EU/3/11/886 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3799 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/019/11/T/03

Europe -DG Health and Food Safety

30-5-2018

Eviplera (Gilead Sciences Ireland UC)

Eviplera (Gilead Sciences Ireland UC)

Eviplera (Active substance: emtricitabine / rilpivirine (as hydrochloride) / tenofovir disoproxil (as fumarate)) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3453 of Wed, 30 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2312/T/91

Europe -DG Health and Food Safety

30-5-2018

Vokanamet (Janssen-Cilag International NV)

Vokanamet (Janssen-Cilag International NV)

Vokanamet (Active substance: canagliflozin / metformin hydrochloride) - Centralised - Yearly update - Commission Decision (2018)3463 of Wed, 30 May 2018

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2017 (Spedding Research Solutions SAS)

EU/3/18/2017 (Spedding Research Solutions SAS)

EU/3/18/2017 (Active substance: Ambroxol hydrochloride) - Orphan designation - Commission Decision (2018)3384 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/236/17

Europe -DG Health and Food Safety

24-5-2018

Velmetia (Merck Sharp and Dohme Limited)

Velmetia (Merck Sharp and Dohme Limited)

Velmetia (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3261 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708

Europe -DG Health and Food Safety

24-5-2018

Ristfor (Merck Sharp and Dohme Limited)

Ristfor (Merck Sharp and Dohme Limited)

Ristfor (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3262 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708

Europe -DG Health and Food Safety

24-5-2018

Janumet (Merck Sharp and Dohme Limited)

Janumet (Merck Sharp and Dohme Limited)

Janumet (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3260 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708

Europe -DG Health and Food Safety

24-5-2018

Efficib (Merck Sharp and Dohme Limited)

Efficib (Merck Sharp and Dohme Limited)

Efficib (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3276 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708

Europe -DG Health and Food Safety